Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing and delivering T cell receptor (TCR)–based immunotherapies designed to treat cancer, autoimmune diseases, and infectious diseases. The company operates primarily within the biopharmaceutical and biotechnology industries, with a core emphasis on redirecting the immune system to recognize and eliminate diseased cells that are not adequately addressed by conventional antibody-based therapies.
The company’s primary revenue driver is KIMMTRAK® (tebentafusp-tebn), an FDA- and EMA-approved therapy for HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma. Immunocore’s unique positioning is based on its proprietary ImmTAX® (Immune mobilizing monoclonal TCRs Against X disease) platform, which combines engineered high-affinity TCRs with immune-activating effector functions, enabling the targeting of intracellular antigens previously considered inaccessible. Founded in 2008 as a spin-out from UK academic research, Immunocore has evolved from a discovery-stage company into a fully integrated biopharmaceutical organization with commercial operations.
Business Operations
Immunocore generates revenue primarily through the commercialization of KIMMTRAK®, with additional revenue historically derived from strategic collaborations and milestone payments. The company operates as a single integrated business centered on the discovery, development, manufacturing, and commercialization of TCR-based therapeutics, with its pipeline spanning oncology, autoimmune, and infectious disease indications.
Operations include proprietary research and development using the ImmTAX® platform, internal clinical development capabilities, and commercial infrastructure supporting oncology markets. Manufacturing is supported through a combination of internal capabilities and external partners. Immunocore maintains subsidiaries including Immunocore Ltd. in the United Kingdom and Immunocore Ireland Limited, which support research, development, and operational functions. The company has also entered into past and present collaborations with large pharmaceutical partners for specific pipeline programs, though its lead commercial asset is fully owned.
Strategic Position & Investments
Immunocore’s strategic direction centers on expanding the clinical and commercial potential of its ImmTAX® technology beyond uveal melanoma into additional solid tumors and non-oncology indications. Growth initiatives include advancing a diversified clinical pipeline, pursuing label expansion opportunities for KIMMTRAK®, and developing next-generation TCR-based modalities with enhanced specificity and safety profiles.
The company has made significant long-term investments in proprietary TCR discovery, protein engineering, and translational immunology. Notable pipeline assets include candidates targeting PRAME and other cancer-associated antigens, as well as programs in autoimmune disease designed to selectively eliminate pathogenic immune cells. As of publicly available disclosures, Immunocore has not pursued large-scale transformative acquisitions; instead, it emphasizes internal innovation and selective partnerships to maximize platform value.
Geographic Footprint
Immunocore is headquartered in Oxford, United Kingdom, with its U.S. commercial and corporate headquarters located in Conshohocken, Pennsylvania. The company operates across Europe and North America, with clinical trials conducted in multiple countries and commercial activities focused primarily on the United States and European Union.
The company’s international footprint reflects its dual focus on global clinical development and commercialization in specialized oncology markets. Ireland plays a role in corporate and operational structuring, while research activities remain concentrated in the UK. Immunocore’s therapies reach patients across multiple continents through a combination of direct commercialization and established healthcare distribution channels.
Leadership & Governance
Immunocore is led by an experienced management team with backgrounds in biotechnology, pharmaceuticals, and immunology, guiding the company’s transition from a research-focused organization to a commercial-stage enterprise. The leadership emphasizes scientific rigor, disciplined capital allocation, and long-term platform development to address high-unmet-need diseases.
Key executives include:
- Bahija Jallal – Chief Executive Officer
- David B. Berman – Executive Vice President, Research & Development
- Rodger Novak – Executive Vice President, Chief Operating Officer
- Fahim Ahmad – Chief Financial Officer
- Nick Viner – Senior Vice President, Translational Sciences
The board and executive team collectively articulate a strategic vision centered on leveraging TCR biology to redefine what targets are druggable, with governance practices aligned to public-company standards following Immunocore’s NASDAQ listing.